The Avian Influenza Trilogy

There are many uncertainties, starting from which vaccine and its content, the effects, the apparent absence of an open competitive tendering process and the UKHSA’s refusal to disclose the cost and any risk-benefit analysis they may have carried out. - Tom Jefferson and Carl Heneghan 

• We focused on the difficult job of understanding the whys and wherefores of the UKHSA’s purchase of more than 5 million doses of an Influenza H5 pandemic vaccine...
• Even more worrying is the fact that TTE had sight of a response from the UKHSA indicating that the purchased vaccines are “expected” to diminish mortality...
• The fragmentation of documents and persistent stonewalling are not good signs...